63/120
2.6 / 5 stars
All 120 Win/Lose results shown below
CRL Roast Me summary
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCRL / S&P 31.47% / 15.20% |
LoseCRL / S&P -0.74% / 15.00% |
LoseCRL / S&P CRL unavailable / 50.40% |
| 2026-Q10/3 |
LoseCRL / S&P -13.53% / -4.33% |
LoseCRL / S&P 0.11% / 11.30% |
LoseCRL / S&P CRL unavailable / 27.70% |
| 2025-Q41/3 |
WinCRL / S&P 27.50% / 2.65% |
LoseCRL / S&P -0.85% / 9.00% |
LoseCRL / S&P -1555.00% / 13.40% |
| 2025-Q30/3 |
LoseCRL / S&P 3.12% / 8.12% |
LoseCRL / S&P -0.92% / 4.61% |
LoseCRL / S&P -118.85% / 13.45% |
| 2025-Q20/3 |
LoseCRL / S&P 0.80% / 10.94% |
LoseCRL / S&P -1.21% / 4.83% |
LoseCRL / S&P -115.29% / 10.63% |
| 2025-Q10/3 |
LoseCRL / S&P -18.46% / -4.27% |
LoseCRL / S&P -2.16% / 4.98% |
LoseCRL / S&P -107.04% / 10.57% |
| 2024-Q40/3 |
LoseCRL / S&P -6.28% / 2.41% |
LoseCRL / S&P -1.92% / 5.25% |
LoseCRL / S&P -97.83% / 6.15% |
| 2024-Q30/3 |
LoseCRL / S&P -4.65% / 5.89% |
LoseCRL / S&P -3.67% / 5.89% |
LoseCRL / S&P -13.31% / 6.11% |
| 2024-Q20/3 |
LoseCRL / S&P -23.76% / 4.28% |
LoseCRL / S&P -2.41% / 5.38% |
LoseCRL / S&P -11.24% / 5.12% |
| 2024-Q11/3 |
WinCRL / S&P 14.62% / 10.56% |
LoseCRL / S&P 0.49% / 5.71% |
LoseCRL / S&P -11.89% / 5.59% |
| 2023-Q41/3 |
WinCRL / S&P 20.62% / 11.69% |
LoseCRL / S&P 3.86% / 6.81% |
LoseCRL / S&P -2.74% / 7.78% |
| 2023-Q32/3 |
LoseCRL / S&P -6.79% / -3.27% |
WinCRL / S&P 11.49% / 7.52% |
WinCRL / S&P 8.83% / -5.03% |
| 2023-Q22/3 |
LoseCRL / S&P 4.18% / 8.74% |
WinCRL / S&P 13.29% / 9.50% |
WinCRL / S&P 9.40% / -8.57% |
| 2023-Q12/3 |
LoseCRL / S&P -7.38% / 7.50% |
WinCRL / S&P 12.73% / 10.77% |
WinCRL / S&P 17.78% / -15.69% |
| 2022-Q43/3 |
WinCRL / S&P 10.72% / 7.56% |
WinCRL / S&P 12.31% / 11.88% |
WinCRL / S&P 24.74% / -17.99% |
| 2022-Q31/3 |
LoseCRL / S&P -8.02% / -4.88% |
LoseCRL / S&P 10.37% / 13.47% |
WinCRL / S&P 9.69% / -1.41% |
| 2022-Q21/3 |
LoseCRL / S&P -24.65% / -16.10% |
LoseCRL / S&P 12.66% / 13.71% |
WinCRL / S&P 11.08% / 11.04% |
| 2022-Q11/3 |
LoseCRL / S&P -24.63% / -4.60% |
WinCRL / S&P 19.34% / 15.97% |
LoseCRL / S&P 11.25% / 42.23% |
| 2021-Q41/3 |
LoseCRL / S&P -8.70% / 11.03% |
WinCRL / S&P 21.08% / 15.00% |
LoseCRL / S&P 5.56% / 96.40% |
| 2021-Q32/3 |
WinCRL / S&P 11.56% / 0.58% |
WinCRL / S&P 21.32% / 10.77% |
LoseCRL / S&P 29.00% / 69.42% |
| 2021-Q22/3 |
WinCRL / S&P 27.63% / 8.55% |
WinCRL / S&P 19.09% / 6.58% |
LoseCRL / S&P 42.91% / 51.81% |
| 2021-Q13/3 |
WinCRL / S&P 16.00% / 6.17% |
WinCRL / S&P 11.67% / -1.06% |
WinCRL / S&P 48.49% / 7.39% |
| 2020-Q42/3 |
LoseCRL / S&P 10.34% / 12.15% |
WinCRL / S&P 11.55% / -3.72% |
WinCRL / S&P 42.01% / -33.42% |
| 2020-Q33/3 |
WinCRL / S&P 29.88% / 8.93% |
WinCRL / S&P 11.55% / -2.04% |
WinCRL / S&P 28.21% / -27.10% |
| 2020-Q23/3 |
WinCRL / S&P 38.14% / 20.54% |
WinCRL / S&P 12.24% / -0.46% |
WinCRL / S&P 22.30% / -27.11% |
| 2020-Q13/3 |
WinCRL / S&P -17.38% / -19.60% |
WinCRL / S&P 14.60% / 3.47% |
WinCRL / S&P 6.65% / -14.75% |
| 2019-Q43/3 |
WinCRL / S&P 15.40% / 9.07% |
WinCRL / S&P 15.67% / 5.36% |
WinCRL / S&P 9.74% / 2.99% |
| 2019-Q32/3 |
LoseCRL / S&P -6.72% / 1.70% |
WinCRL / S&P 18.13% / 5.02% |
WinCRL / S&P 68.35% / 0.21% |
| 2019-Q22/3 |
LoseCRL / S&P -2.31% / 4.30% |
WinCRL / S&P 21.12% / 6.64% |
WinCRL / S&P 68.18% / 8.65% |
| 2019-Q13/3 |
WinCRL / S&P 28.34% / 13.65% |
WinCRL / S&P 24.71% / 8.12% |
WinCRL / S&P 75.19% / 14.29% |
| 2018-Q42/3 |
LoseCRL / S&P -15.88% / -13.52% |
WinCRL / S&P 21.99% / 9.05% |
WinCRL / S&P 81.89% / 18.23% |
| 2018-Q32/3 |
WinCRL / S&P 19.85% / 7.71% |
WinCRL / S&P 16.10% / 10.21% |
LoseCRL / S&P -32.20% / 19.06% |
| 2018-Q22/3 |
WinCRL / S&P 5.17% / 3.43% |
WinCRL / S&P 11.87% / 9.03% |
LoseCRL / S&P -30.71% / 14.46% |
| 2018-Q10/3 |
LoseCRL / S&P -2.48% / -0.76% |
LoseCRL / S&P 7.53% / 7.68% |
LoseCRL / S&P -22.22% / 12.46% |
| 2017-Q41/3 |
LoseCRL / S&P 1.32% / 6.64% |
WinCRL / S&P 10.48% / 7.03% |
LoseCRL / S&P -21.36% / 13.82% |
| 2017-Q33/3 |
WinCRL / S&P 6.79% / 4.48% |
WinCRL / S&P 17.69% / 5.68% |
WinCRL / S&P 38.51% / 17.57% |
| 2017-Q23/3 |
WinCRL / S&P 12.45% / 3.09% |
WinCRL / S&P 21.12% / 4.83% |
WinCRL / S&P 28.72% / 17.74% |
| 2017-Q12/3 |
WinCRL / S&P 18.06% / 6.07% |
WinCRL / S&P 26.80% / 3.67% |
LoseCRL / S&P 5.23% / 13.32% |
| 2016-Q41/3 |
LoseCRL / S&P -8.58% / 3.82% |
WinCRL / S&P 23.34% / 2.09% |
LoseCRL / S&P 3.19% / 7.05% |
| 2016-Q32/3 |
LoseCRL / S&P 1.09% / 3.85% |
WinCRL / S&P 17.14% / 0.20% |
WinCRL / S&P -2.63% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | CRL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 78.50% | 20.78% |
| Annualized return | 78.50% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | CRL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -34.31% | 83.14% |
| Annualized return | -8.06% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | CRL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 248.70% | 319.30% |
| Annualized return | 13.30% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |